The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: A retrospective cohort study using a US health insurance database

Clinical Therapeutics

Volumn 31, Issue 11, 2009, Pages 2665-2677

  Ziyadeh, Najat ^a   McAfee, Andrew T ^a,b   Koro, Carol ^c,d   Landon, Joan ^a   Arnold Chan, K ^a,e  

^a i3 Drug Safety   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c GLAXOSMITHKLINE   (United States)

^d UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

coronary revascularization; insulin; myocardial infarction; pioglitazone; propensity score matching; retrospective cohort study; rosiglitazone; sudden death

Indexed keywords

ACARBOSE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EXENDIN 4; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; METFORMIN; MIGLITOL; NATEGLINIDE; NITRATE; PIOGLITAZONE; PRAMLINTIDE; REPAGLINIDE; ROSIGLITAZONE; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH INSURANCE; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROPORTIONAL HAZARDS MODEL; RISK ASSESSMENT; SIDE EFFECT; SUDDEN DEATH; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; COHORT STUDIES; CORONARY DISEASE; DEATH, SUDDEN; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; THIAZOLIDINEDIONES; TREATMENT OUTCOME; UNITED STATES;

EID: 74549202936     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.003     Document Type: Article

References (23)

1. Malesker M.A. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities. Pharmacotherapy 28 (2008) 193-206
2. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes [published correction appears in N Engl J Med. 2007;357:100]. N Engl J Med. 356 (2007) 2457-2471
3. Singh S., Loke Y.K., and Furberg C.D. Longterm risk of cardiovascular events with rosiglitazone: A meta-analysis. JAMA 298 (2007) 1189-1195
4. Home P.D., Pocock S.J., Beck-Nielsen H., et al., RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes-an interim analysis. N Engl J Med. 357 (2007) 28-38
5. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators, Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomised controlled trial [published correction appears in Lancet. 2006;368:1770]. Lancet 368 (2006) 1096-1105
6. Kahn S.E., Haffner S.M., Heise M.A., et al., ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy [published correction appears in N Engl J Med. 2007;356:1387-1388]. N Engl J Med. 355 (2006) 2427-2443
7. Avandia (rosiglitazone maleate) tablets [package insert] (2007), GlaxoSmithKline, Research Triangle Park, NC. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021071s034lbl.pdf Accessed July 11, 2008
8. McAfee A.T., Koro C., Landon J., et al. Coronary heart disease outcomes in patients receiving antidiabetic agents. Pharmacoepidemiol Drug Saf. 16 (2007) 711-725
9. Johannes C.B., Koro C.E., Quinn S.G., et al. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. Pharmacoepidemiol Drug Saf. 16 (2007) 504-512
10. Gerrits C.M., Bhattacharya M., Manthena S., et al. A comparison of pioglitazone and rosiglitazone for hospitalization for acute myocardial infarction in type 2 diabetes. Pharmacoepidemiol Drug Saf. 16 (2007) 1065-1071
11. Walker A.M., Koro C.E., and Landon J. Coronary heart disease outcomes in patients receiving antidiabetic agents in the PharMetrics database 2000-2007. Pharmacoepidemiol Drug Saf. 17 (2008) 760-768
12. Lanza L.L., Walker A.M., Bortnichak E.A., and Dreyer N.A. Peptic ulcer and gastrointestinal hemorrhage associated with nonsteroidal anti-inflammatory drug use in patients younger than 65 years of age: A large health maintenance organization cohort study. Arch Intern Med. 155 (1995) 1371-1377
13. Velentgas P., West W., Cannuscio C.C., et al. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal antiinflammatory medications. Pharmacoepidemiol Drug Saf. 15 (2006) 641-652
14. Epstein M., and International Society of Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 14 (2005) 589-595
15. Rezulin to be withdrawn from the market. FDA News (March 21, 2000). http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3634b1a_tab6c.htm Accessed September 10, 2009
16. Enger C., Cali C., and Walker A.M. Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. Pharmacoepidemiol Drug Saf. 11 (2002) 477-486
17. Parsons L.S. Reducing bias in a propensity-score matched-pair sample using greedy matching techniques. Proceedings of the Twenty-Sixth Annual SAS Users Group International Conference (2001), SAS Institute Inc, Cary, NC. http://www2.sas.com/proceedings/sugi26/p214-26.pdf Accessed November 29, 2007
18. Seeger J.D., Williams P.L., and Walker A.M. An application of propensity score matching using claims data. Pharmacoepidemiol Drug Saf. 14 (2005) 465-476
19. Strom B.L., and Lewis J.D. In clarification. Pharmacoepidemiol Drug Saf. 16 (2007) 1063-1064
20. Cobitz A., Zambanini A., Sowell M., et al. A retrospective evaluation of congestive heart failure and myocardial ischemia events in 14,237 patients with type 2 diabetes mellitus enrolled in 42 shortterm, double blind, randomized clinical studies in rosiglitazone. Pharmacoepidemiol Drug Saf. 17 (2008) 769-781
21. Lipscombe L.L., Gomes T., Lévesque L.E., et al. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes. JAMA 298 (2007) 2634-2643
22. Margolis D.J., Hoffstad O., and Strom B.L. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf. 17 (2008) 753-759
23. Casscells S.W., Granger E., Swedorske J., et al. A comparison of select cardiovascular outcomes by antidiabetic prescription drug classes used to treat type 2 diabetes among Military Health System beneficiaries, fiscal year 2003-2006. Am J Ther. 15 (2008) 198-205